These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

762 related items for PubMed ID: 16142849

  • 1. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD, Faber H, Fahramand P, Schacht E.
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [Abstract] [Full Text] [Related]

  • 2. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
    Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW.
    Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
    [Abstract] [Full Text] [Related]

  • 3. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY, Lecart MP, Richy F.
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [Abstract] [Full Text] [Related]

  • 4. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
    Scharla SH, Schacht E, Lempert UG.
    J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
    [Abstract] [Full Text] [Related]

  • 5. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD, Farahmand P, Schacht E, Rozehnal A.
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [Abstract] [Full Text] [Related]

  • 6. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
    Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY.
    Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
    [Abstract] [Full Text] [Related]

  • 7. [Therapy of glucocorticoid-induced osteoporosis with alfacalcidol/calcium and vitamin D/calcium].
    Ringe JD, Cöster A, Meng T, Schacht E, Umbach R.
    Z Rheumatol; 2000 Jun; 59(3):176-82. PubMed ID: 10929446
    [Abstract] [Full Text] [Related]

  • 8. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
    Ringe JD, Farahmand P, Schacht E.
    Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
    Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S.
    J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
    [Abstract] [Full Text] [Related]

  • 11. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 12. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.
    Ringe JD, Cöster A, Meng T, Schacht E, Umbach R.
    Calcif Tissue Int; 1999 Oct; 65(4):337-40. PubMed ID: 10485988
    [Abstract] [Full Text] [Related]

  • 13. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
    Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC.
    J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
    Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M, A-TOP (Adequate Treatment of Osteoporosis) research group.
    Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD, Faber H, Farahmand P, Dorst A.
    Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
    [Abstract] [Full Text] [Related]

  • 19. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM, Hillner BE.
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.